HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY), maintaining a price target of $4.5.

March 08, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Unicycive Therapeutics with a $4.5 price target.
The reiteration of a Buy rating and maintenance of a $4.5 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Unicycive Therapeutics. This endorsement serves as a strong signal of confidence in the company's future performance, potentially leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100